Logo
Hepat Mon

Image Credit:Hepat Mon

Liver Histopathology of Deceased Patients with COVID-19: A Case Series from Tehran, Iran

Author(s):
Mousa AhmadiMousa AhmadiMousa Ahmadi ORCID1, Shadi MohammadiShadi MohammadiShadi Mohammadi ORCID2, Mahtab FotoohiMahtab Fotoohi3, Morteza AghajanpoorMorteza Aghajanpoor4, Ramin YaghmayeeRamin Yaghmayee3, Jalil RajabiJalil RajabiJalil Rajabi ORCID1, Besharat ZarezadehBesharat Zarezadeh5, Saeed Soleiman-MeigooniSaeed Soleiman-MeigooniSaeed Soleiman-Meigooni ORCID6,*
1Department of Infectious Diseases, Faculty of Medicine, AJA University of Medical Sciences, Tehran, Iran
2Department of Obstetrics and Gynecology, Khanevadeh University Hospital, AJA University of Medical Sciences, Tehran, Iran
3Department of Pathology, Khanevadeh University Hospital, AJA University of Medical Sciences, Tehran, Iran
4Department of Gastroenterology and Hepatology, Faculty of Medicine, AJA University of Medical Sciences, Tehran, Iran
5Iranian Research Center for HIV/AIDS, Iranian Institute of High-risk Behaviors, Tehran University of Medical Sciences, Tehran, Iran
6Infectious Diseases Research Center, AJA University of Medical Sciences, Tehran, Iran


Hepatitis Monthly:Vol. 25, issue 1; e157866
Published online:Apr 20, 2025
Article type:Research Article
Received:Nov 11, 2024
Accepted:Apr 09, 2025
How to Cite:Mousa AhmadiShadi MohammadiMahtab FotoohiMorteza AghajanpoorRamin YaghmayeeJalil RajabiBesharat ZarezadehSaeed Soleiman-Meigooniet al.Liver Histopathology of Deceased Patients with COVID-19: A Case Series from Tehran, Iran.Hepat Mon.2025;25(1):e157866.https://doi.org/10.5812/hepatmon-157866.

Abstract

Background:

SARS-CoV-2 receptors are distributed in several vital organs, and many of these organs are damaged in severe COVID-19. Liver inflammation in COVID-19 ranges from asymptomatic elevation of liver transaminase levels to fulminant hepatitis.

Objectives:

The present study aimed to investigate the liver histopathology of deceased patients with COVID-19.

Methods:

This case series study was conducted in Tehran, Iran, in 2021. The subjects were deceased patients with COVID-19. After obtaining informed consent from the first-degree relatives, at least two liver tissue samples were obtained through the right 10th to 12th intercostal spaces using a biopsy needle, following the Helsinki biopsy guidelines. Clinical information from the patients was extracted using a questionnaire. Fisher's exact test and Student’s t-test were used to analyze the data.

Results:

Liver sampling was performed in 12 deceased patients. The mean age of the patients was 73 years, with a male-to-female ratio of 9:3. The most common clinical cause of death was adult respiratory distress syndrome (ARDS), occurring in eight patients. An increase in liver transaminase levels was observed in four patients. Histopathological examination revealed normal results in three patients, moderate to severe inflammation according to the [non-alcoholic fatty liver disease (NAFLD) activity score (NAS score)] in eight patients, and mild NAS scores in four patients. Liver inflammation was not correlated with other parameters, including sex, diabetes mellitus (DM), chronic renal failure (CRF), transaminase level, Body Mass Index (BMI), C-reactive protein (CRP) level, or length of stay in hospital. Liver steatosis was observed in four of the 12 patients and was significantly associated with a higher BMI (P = 0.014).

Conclusions:

In our study, most patients exhibited a moderate-to-severe NAS score that did not correlate with disease severity or underlying medical conditions. We recommend regular assessment of clinical and biochemical indicators of liver inflammation in individuals with severe COVID-19.

1. Background

Liver injury is a prevalent form of organ damage in patients with SARS-CoV-2. It is estimated that 14% to 53% of patients with COVID-19 develop abnormal liver function tests (1). The mechanisms of liver damage in COVID-19 are under investigation and appear to have multifactorial etiologies. Liver injury may present with subclinical elevation of aminotransferase levels or fulminant hepatic failure (2, 3). Therefore, SARS-CoV-2-related liver injury has a spectrum of histopathological features. Autopsy studies have demonstrated steatosis, inflammation, vascular thrombosis, and hepatocyte necrosis in deceased patients with COVID-19 (4-7). According to recent pathology investigations, patients with COVID-19 had a greater rate of steatosis and lobular inflammation than those with other liver diseases. High-dose steroid administration contributes to the occurrence of steatosis (6). Liver injury is associated with prolonged length of stay (LOS) in hospital, higher rates of ICU admission, and increased mortality rates (8). Critically ill patients with COVID-19 exhibit increased hepatic failure, suggesting that liver damage is correlated with disease severity (9). Additionally, pre-existing liver disorders, including non-alcoholic fatty liver disease (NAFLD) and chronic viral hepatitis, may exacerbate the risk of liver damage (10). SARS-CoV-2-associated liver damage contributes to unfavorable outcomes in patients with COVID-19.

2. Objectives

In the present study, we aimed to evaluate liver histopathology and its clinical correlation in a series of patients who died of COVID-19.

3. Methods

We conducted a case series study of deceased patients with COVID-19 in Tehran, Iran, between January and May 2021. Subjects were selected through conventional sampling after obtaining written informed consent from their first-degree relatives. One of the authors, wearing protective equipment, including an N95 mask, gown, gloves, and face shield, performed the liver biopsy in a negative pressure room. The procedure was performed using a 16-gauge Jamshidi needle through the 12th right intercostal space. The samples were fixed in formalin and transferred to the pathology department. Subsequently, 10 µm sections were prepared from the samples using a microtome, stained with hematoxylin-eosin, and mounted on slides. Each slide was independently examined by two pathologists, and the final report was compiled through collaboration between the attending physician and pathologists. Additionally, demographic characteristics, underlying conditions, clinical symptoms, and paraclinical findings, including blood cell counts, inflammatory biomarkers, liver function tests, and histological findings, were extracted from their registries. Fisher’s exact test and Student’s t-test were used for data analysis. This study is part of a multi-organ autopsy study in deceased patients with COVID-19, approved by the Ethics Committee of the AJA University of Medical Sciences (IR.AJAUMS.REC.1399.030).

4. Results

During the study period, 12 deceased COVID-19 patients underwent liver biopsies. Of these, three were female and nine were male. The mean age of the patients was 73 ± 14.3 years, the mean Body Mass Index (BMI) was 26.6 ± 4, and the mean LOS was 12.3 ± 3.3 days. The frequencies of underlying diseases included hypertension (HTN) in 11 patients (91.7%), ischemic heart disease (IHD) in eight patients (66.7%), diabetes mellitus (DM) in five patients (41.7%), and chronic renal failure (CRF) in three patients (25%). The most common symptoms on admission were dyspnea in 11 patients (91.7%), cough in nine patients (75%), fever in seven patients (58.3%), malaise, and decreased level of consciousness in six patients (50%). The most common clinical cause of death was adult respiratory distress syndrome (ARDS), which occurred in eight patients (66.7%).

Table 1 presents the demographic characteristics, clinical symptoms, and laboratory findings of patients on admission. Histopathological examination revealed portal and periportal inflammation as the predominant findings in nine patients (75%), followed by microvesicular steatosis in four patients (33.3%) and interstitial edema in three patients (25%) (Figure 1). Hepatic inflammation was classified as minimal to mild in four individuals and moderate to severe in eight patients according to the NAFLD activity score (NAS score). The Student’s t-test (Table 2) did not reveal any correlation between the NAS score and age, BMI, LOS, C-reactive protein (CRP), lactate dehydrogenase (LDH), and alanine transaminase (ALT) levels. Additionally, Fisher's exact test did not reveal any correlation between NAS score and sex, DM, CRF, or etiology of mortality (Table 3). Patients with steatosis exhibited a higher BMI than those without steatosis (30.2 ± 3.6 vs. 24.7 ± 2.8, respectively; P = 0.014).

Table 1.Demographic Characteristics and Laboratory Finding of the Study Population (N = 12)
CasesAgeSexBMI (kg/m2)LOSALCANCHbPLT (× 103 U/L)CRP (mg/L)LDH (< 450 U/L)ALT (< 40 IU/L)PMHClinical Cause of DeathHepatic Inflammation by NAS ScoreLiver Pathology
178F247873834214.91439276513HTN, CRFPTEModerate activity, 3 pointsPortal and periportal mixed inflammation, ballooning degeneration, edema
279F2912640672012.1317231016HTN, DMARDSMild activity, 2 pointsPortal and periportal mixed inflammation, ballooning degeneration
370F2717666296014.41366575378HTNPTEModerate activity, 5 pointsPortal and periportal mixed inflammation , microvesicolar steatosis, focal necrosis, ballooning degeneration, edema
435M35819101680811.43216484484HTN, IHD, DMARDSModerate activity, 3 pointsMild inflammation, microvesicolar steatosis
579M3110770451014.811543157313HTN, IHDARDSModerate activity, 4 pointsMild inflammation, microvesicolar steatosis
678M211212621050012.72125428024HTN, CRFARDSSevere activity, 7 pointsPortal and periportal mixed inflammation, ballooning degeneration, edema
793M241212211557613.81626869333NoneARDSModerate activity, 4 pointsPortal and periportal mixed inflammation, ballooning degeneration
869M28103250207509.23976647666HTN, IHDARDSModerate activity, 4 pointsPortal and periportal mixed inflammation and hemorrhage, microvesicolar steatosis
964M28131137415213.81374682733HTN, IHD, DMPTEModerate activity, 4 pointsPortal and periportal mixed inflammation, hemorrhage
1075M2417567567012.71907461434HTN, IHDSepsis and MOFNormalNormal
1170M221622501232013.91267236530HTN, IHD, DM, CRFSepsis and MOFNormalNormal
1286M2614336204012.7835855045HTN, IHD, DMPTENormalNormal

Demographic Characteristics and Laboratory Finding of the Study Population (N = 12)

Liver histopathology of deceased patients with COVID-19. Yellow arrow, portal and periportal mixed inflammation; cyan arrow, microvesicolar steatosis; red arrow, mild inflammation; black arrow, hemorrhage; blue arrow, hepatocyte injury, ballooning degeneration; pea green arrow, edema.
Figure 1.

Liver histopathology of deceased patients with COVID-19. Yellow arrow, portal and periportal mixed inflammation; cyan arrow, microvesicolar steatosis; red arrow, mild inflammation; black arrow, hemorrhage; blue arrow, hepatocyte injury, ballooning degeneration; pea green arrow, edema.

Table 2.Liver Histopathology in the Subgroups of the Study Population (N = 12)
VariablesNAS ScoreP-Value (Fisher’s Exact Test)
Normal or Mild Score (n = 4)Moderate or Severe Score (n = 8)
Gender1.000
Male36
Female12
DM0.081
Yes43
No05
CRF1.000
Yes12
No36
Death etiology0.067
ARDS17
PTE11
Sepsis20

Liver Histopathology in the Subgroups of the Study Population (N = 12)

Table 3.Liver Histopathology in the Subgroups of the Study Population (N = 12)
VariablesNAS ScoreP-Value (t-Test)
Normal or Mild Score (n = 4)Moderate or Severe Score (n = 8)
Age73 ± 12.570.7 ± 16.90.820
BMI27 ± 3.927.2 ± 4.40.926
LOS16.7 ± 22.25.9 ± 2.10.180
CRP42.5 ± 30.462.2 ± 15.30.156
LDH416 ± 104776 ± 3750.095
ALT26.5 ± 14.143 ± 28.70.312

Liver Histopathology in the Subgroups of the Study Population (N = 12)

5. Discussion

Our study is one of the few investigations focused on liver histopathology in patients with COVID-19. The most common histopathological finding was inflammation (75%), followed by steatosis (33.3%). Most patients were classified as having moderate or severe NAS scores, indicating the severity of liver injury in COVID-19. Our findings underscore the importance of liver involvement in patients with severe COVID-19. Furthermore, steatosis was more common in patients with a BMI > 30. Similar studies have reported steatosis, inflammation, and necrosis as primary findings in liver pathology. The primary liver histological characteristics linked to SARS-CoV-2 infection include steatosis, portal and periportal inflammation, vascular thrombosis, and hepatocyte necrosis (4, 5, 9-14). However, we did not observe portal thrombosis in our subjects, which may be attributable to the small sample size or population differences. We also did not find fibrotic changes in our patients. Prolonged liver inflammation may result in hepatic fibrosis in patients with liver diseases (15). We suggest that since only a quarter of our patients exhibited increased transaminases and none had a history of chronic viral hepatitis, along with the acute nature of inflammation triggered by COVID-19, the development of fibrosis seemed unlikely. Although we did not find any correlation between the NAS score and other clinical or paraclinical parameters, this may be related to our limited sample size.

Angiotensin-converting enzyme 2 (ACE2) is a specific receptor for SARS-CoV-2 and is present in several vital organs (16). Autopsy studies have revealed severe inflammation and damage to the lungs, heart, brain, kidney, and liver in a high percentage of patients with severe COVID-19 (17-20). The most common finding of liver injury during SARS-CoV-2 infection is elevated transaminase levels (1, 21, 22). Furthermore, some patients develop cholestasis and elevated alkaline phosphatase and bilirubin levels (23). Acute hepatic failure is a rare condition that develops in severe COVID-19 cases (3, 24). Several mechanisms have been proposed for liver injury during SARS-CoV-2 infection, including direct SARS-CoV-2 invasion (25), immune-mediated injury after cytokine storms (26), hypoxia-related liver injury (27), coagulopathy (28), and drug-induced hepatotoxicity, such as corticosteroids resulting in steatosis, or remdesivir resulting in hepatitis (14, 29). Pre-existing hepatic conditions, advanced age, and severe COVID-19 increase the likelihood of hepatic complications (10).

Previous studies have reported that liver injury in patients with COVID-19 is associated with prolonged LOS, higher rates of ICU admission, and increased mortality rates (8). Although studies have suggested a correlation between liver inflammation and disease severity, we did not find any correlation between the NAS score and CRP levels in our study (9, 14). While additional research is required to definitively ascertain the relationship between liver inflammation and COVID-19-related mortality, existing evidence indicates that hepatic inflammation significantly influences the prognosis and outcome of COVID-19. Despite the absence of an association between the NAS score and the history of DM, CRF, CRP levels, or BMI, this inconsistency may be attributable to the limited sample size of our study.

5.1. Limitations

Our study has several limitations. The principal limitation was the absence of a control group to compare liver pathology in hypoxic-ischemic liver injury with that in viral hepatitis. Another challenge was the absence of prior liver function tests, which affected liver pathology before admission. Finally, our study was conducted with a small subject group, which may limit the generalizability of our findings.

5.2. Conclusions

Our study revealed a high percentage of liver involvement in deceased COVID-19 patients. Therefore, clinicians should monitor liver function in patients with COVID-19, particularly in those with preexisting liver conditions.

Footnotes

References

  • 1.
    Vishwajeet V, Purohit A, Kumar D, Parag V, Tripathi S, Kanchan T, et al. Evaluation of Pathological Findings of COVID-19 by Minimally Invasive Autopsies: A Single Tertiary Care Center Experience from India. J Lab Physicians. 2021;13(2):97-106. [PubMed ID: 34483552]. [PubMed Central ID: PMC8409114]. https://doi.org/10.1055/s-0041-1730750.
  • 2.
    Wijarnpreecha K, Ungprasert P, Panjawatanan P, Harnois DM, Zaver HB, Ahmed A, et al. COVID-19 and liver injury: a meta-analysis. Eur J Gastroenterol Hepatol. 2021;33(7):990-5. [PubMed ID: 32639420]. [PubMed Central ID: PMC8162043]. https://doi.org/10.1097/MEG.0000000000001817.
  • 3.
    Melquist S, Estepp K, Aleksandrovich Y, Lee A, Beiseker A, Hamedani FS, et al. COVID-19 presenting as fulminant hepatic failure: A case report. Medicine (Baltimore). 2020;99(43). e22818. [PubMed ID: 33120805]. [PubMed Central ID: PMC7581048]. https://doi.org/10.1097/MD.0000000000022818.
  • 4.
    Sonzogni A, Previtali G, Seghezzi M, Grazia Alessio M, Gianatti A, Licini L, et al. Liver histopathology in severe COVID 19 respiratory failure is suggestive of vascular alterations. Liver Int. 2020;40(9):2110-6. [PubMed ID: 32654359]. [PubMed Central ID: PMC7404964]. https://doi.org/10.1111/liv.14601.
  • 5.
    Chornenkyy Y, Mejia-Bautista M, Brucal M, Blanke T, Dittmann D, Yeldandi A, et al. Liver Pathology and SARS-CoV-2 Detection in Formalin-Fixed Tissue of Patients With COVID-19. Am J Clin Pathol. 2021;155(6):802-14. [PubMed ID: 33914058]. [PubMed Central ID: PMC8135761]. https://doi.org/10.1093/ajcp/aqab009.
  • 6.
    Righi FA, Vander Heide RS, Graham RP, Aubry MC, Trejo-Lopez JA, Bois MC, et al. A case-control autopsy series of liver pathology associated with novel coronavirus disease (COVID-19). Ann Diagn Pathol. 2024;68:152240. [PubMed ID: 37995413]. https://doi.org/10.1016/j.anndiagpath.2023.152240.
  • 7.
    Bidari Zerehpoosh F, Sabeti S, Bahrami-Motlagh H, Mokhtari M, Naghibi Irvani SS, Torabinavid P, et al. Post-mortem Histopathologic Findings of Vital Organs in Critically Ill Patients with COVID-19. Arch Iran Med. 2021;24(2):144-51. [PubMed ID: 33636984]. https://doi.org/10.34172/aim.2021.23.
  • 8.
    Kondo R, Kawaguchi N, McConnell MJ, Sonzogni A, Licini L, Valle C, et al. Pathological characteristics of liver sinusoidal thrombosis in COVID-19 patients: A series of 43 cases. Hepatol Res. 2021;51(9):1000-6. [PubMed ID: 34260803]. [PubMed Central ID: PMC8444906]. https://doi.org/10.1111/hepr.13696.
  • 9.
    Chu H, Peng L, Hu L, Zhu Y, Zhao J, Su H, et al. Liver Histopathological Analysis of 24 Postmortem Findings of Patients With COVID-19 in China. Front Med (Lausanne). 2021;8:749318. [PubMed ID: 34708059]. [PubMed Central ID: PMC8543004]. https://doi.org/10.3389/fmed.2021.749318.
  • 10.
    Fassan M, Mescoli C, Sbaraglia M, Guzzardo V, Russo FP, Fabris R, et al. Liver histopathology in COVID-19 patients: A mono-Institutional series of liver biopsies and autopsy specimens. Pathol Res Pract. 2021;221:153451. [PubMed ID: 33932720]. [PubMed Central ID: PMC8054534]. https://doi.org/10.1016/j.prp.2021.153451.
  • 11.
    Lax SF, Skok K, Zechner P, Kessler HH, Kaufmann N, Koelblinger C, et al. Pulmonary Arterial Thrombosis in COVID-19 With Fatal Outcome : Results From a Prospective, Single-Center, Clinicopathologic Case Series. Ann Intern Med. 2020;173(5):350-61. [PubMed ID: 32422076]. [PubMed Central ID: PMC7249507]. https://doi.org/10.7326/M20-2566.
  • 12.
    Falasca L, Nardacci R, Colombo D, Lalle E, Di Caro A, Nicastri E, et al. Postmortem Findings in Italian Patients With COVID-19: A Descriptive Full Autopsy Study of Cases With and Without Comorbidities. J Infect Dis. 2020;222(11):1807-15. [PubMed ID: 32914853]. [PubMed Central ID: PMC7543426]. https://doi.org/10.1093/infdis/jiaa578.
  • 13.
    Hanley B, Naresh KN, Roufosse C, Nicholson AG, Weir J, Cooke GS, et al. Histopathological findings and viral tropism in UK patients with severe fatal COVID-19: a post-mortem study. Lancet Microbe. 2020;1(6):e245-53. [PubMed ID: 32844161]. [PubMed Central ID: PMC7440861]. https://doi.org/10.1016/S2666-5247(20)30115-4.
  • 14.
    Zhao SW, Li YM, Li YL, Su C. Liver injury in COVID-19: Clinical features, potential mechanisms, risk factors and clinical treatments. World J Gastroenterol. 2023;29(2):241-56. [PubMed ID: 36687127]. [PubMed Central ID: PMC9846943]. https://doi.org/10.3748/wjg.v29.i2.241.
  • 15.
    Kolesova O, Vanaga I, Laivacuma S, Derovs A, Kolesovs A, Radzina M, et al. Intriguing findings of liver fibrosis following COVID-19. BMC Gastroenterol. 2021;21(1):370. [PubMed ID: 34635073]. [PubMed Central ID: PMC8503733]. https://doi.org/10.1186/s12876-021-01939-7.
  • 16.
    Li R, Qin C. Expression pattern and function of SARS-CoV-2 receptor ACE2. Biosaf Health. 2021;3(6):312-8. [PubMed ID: 34466800]. [PubMed Central ID: PMC8393493]. https://doi.org/10.1016/j.bsheal.2021.08.003.
  • 17.
    Nouri M, Soleiman-Meigooni S, Mohammadi S, Sakhabakhsh M, Yaghmayee R, Fotoohi M. Neuropathology of 30 deceased patients with COVID-19: A case series in Tehran, Iran. Ann Med Surg (Lond). 2023;85(2):271-5. [PubMed ID: 36845816]. [PubMed Central ID: PMC9949774]. https://doi.org/10.1097/MS9.0000000000000203.
  • 18.
    Soleiman-Meigooni S, Yaghmayee R, Mohammadi S, Ahmadi M, Sakhabakhsh M, Hamidi-Farahani R, et al. Cardio-Pulmonary Histopathology with Clinical Correlations of Deceased Patients with COVID-19: A Case Series in Tehran, Iran. Arch Iran Med. 2023;26(5):252-60. [PubMed ID: 38301088]. [PubMed Central ID: PMC10685862]. https://doi.org/10.34172/aim.2023.39.
  • 19.
    Nava-Santana C, Rodriguez-Armida M, Jimenez JV, Vargas-Parra N, Leon DEA, Campos-Murguia A, et al. Clinicopathologic characteristics of severe COVID-19 patients in Mexico City: A post-mortem analysis using a minimally invasive autopsy approach. PLoS One. 2022;17(3). e0262783. [PubMed ID: 35239660]. [PubMed Central ID: PMC8893646]. https://doi.org/10.1371/journal.pone.0262783.
  • 20.
    Gheban-Rosca IA, Gheban BA, Pop B, Mironescu DC, Siserman VC, Jianu EM, et al. A histopathological analysis of extrapulmonary lesions in fatal coronavirus disease (COVID-19). Pathol Res Pract. 2024;260:155373. [PubMed ID: 38901140]. https://doi.org/10.1016/j.prp.2024.155373.
  • 21.
    Azizmohammadi S, Azizmohammadi S, Dahmardeh S, Hossein A, Shokouh SJH, Mohajeri-Iravani M, et al. Analysis of 239 ordinary and severe cases of COVID-19: Clinical features and treatment. Eur J Transl Myol. 2021;31(3). [PubMed ID: 34579515]. [PubMed Central ID: PMC8495366]. https://doi.org/10.4081/ejtm.2021.9579.
  • 22.
    Hamidi Farahani R, Gholami M, Hazrati E, Hosseini Rouzbahani N, Hejripour Z, Soleiman-Meigooni S, et al. Clinical Features of ICU Admitted and Intubated Novel Corona Virus-infected Patients in Iran. Arch Clin Infect Dis. 2020;15(2). e103295. https://doi.org/10.5812/archcid.103295.
  • 23.
    Diaz LA, Idalsoaga F, Cannistra M, Candia R, Cabrera D, Barrera F, et al. High prevalence of hepatic steatosis and vascular thrombosis in COVID-19: A systematic review and meta-analysis of autopsy data. World J Gastroenterol. 2020;26(48):7693-706. [PubMed ID: 33505145]. [PubMed Central ID: PMC7789052]. https://doi.org/10.3748/wjg.v26.i48.7693.
  • 24.
    Haji Esmaeil Memar E, Mamishi S, Sharifzadeh Ekbatani M, Alimadadi H, Yaghmaei B, Chegini V, et al. Fulminant hepatic failure: A rare and devastating manifestation of Coronavirus disease 2019 in an 11-year-old boy. Arch Pediatr. 2020;27(8):502-5. [PubMed ID: 33069564]. [PubMed Central ID: PMC7522641]. https://doi.org/10.1016/j.arcped.2020.09.009.
  • 25.
    Barnes E. Infection of liver hepatocytes with SARS-CoV-2. Nat Metab. 2022;4(3):301-2. [PubMed ID: 35347317]. https://doi.org/10.1038/s42255-022-00554-4.
  • 26.
    Ali FEM, Mohammedsaleh ZM, Ali MM, Ghogar OM. Impact of cytokine storm and systemic inflammation on liver impairment patients infected by SARS-CoV-2: Prospective therapeutic challenges. World J Gastroenterol. 2021;27(15):1531-52. [PubMed ID: 33958841]. [PubMed Central ID: PMC8058655]. https://doi.org/10.3748/wjg.v27.i15.1531.
  • 27.
    Nunes MC, Hale MJ, Mahtab S, Mabena FC, Dludlu N, Baillie VL, et al. Clinical characteristics and histopathology of COVID-19 related deaths in South African adults. PLoS One. 2022;17(1). e0262179. [PubMed ID: 35051205]. [PubMed Central ID: PMC8775212]. https://doi.org/10.1371/journal.pone.0262179.
  • 28.
    Yadav J, Goel G, Purwar S, Saigal S, Tandon A, Joshi A, et al. Clinical, Virological, and Pathological Profile of Patients Who Died of COVID-19: An Autopsy-Based Study From India. Cureus. 2022;14(3). e23538. https://doi.org/10.7759/cureus.23538.
  • 29.
    Elsoukkary SS, Mostyka M, Dillard A, Berman DR, Ma LX, Chadburn A, et al. Autopsy Findings in 32 Patients with COVID-19: A Single-Institution Experience. Pathobiology. 2021;88(1):56-68. [PubMed ID: 32942274]. [PubMed Central ID: PMC7573917]. https://doi.org/10.1159/000511325.
comments

Leave a comment here


Crossmark
Crossmark
Checking
Share on
Cited by
Metrics

Purchasing Reprints

  • Copyright Clearance Center (CCC) handles bulk orders for article reprints for Brieflands. To place an order for reprints, please click here (   https://www.copyright.com/landing/reprintsinquiryform/ ). Clicking this link will bring you to a CCC request form where you can provide the details of your order. Once complete, please click the ‘Submit Request’ button and CCC’s Reprints Services team will generate a quote for your review.
Search Relations

Author(s):

Related Articles